
## Provider Education Committee Agenda June 9, 2025 | 12:00pm-1:30pm





Welcome and Introductions	Blanca Martinez
TAPI Update	James Washington
ADHS Update	Marcellina Lopez
ADHS 2025 IDR Data	Lauren Krebs
Flu Mist Home	Karen Tan, Pham.D, BCIDP AstraZeneca
National Policy Update	Jennifer Tinney
Communications Conversation and breakout	Karin Szymanski
TAPI Resource Update	Karin Szymanski
TIPS	Karin Szymanski


### NEXT MEETING DATE:

Provider Education Committee Meeting Monday, August 11, 2025 12:00pm - 1:30pm











#### Agenda . Re - enrollment Update . Fall Respiratory Virus Season Vaccine Ordering . Influenza . COVID-19

COVID-19
Shipping Updates

7





#### 2025 VFC Annual Re-Enrollment


- Re-enrollment is currently open and will end August 31, 2025.
- Re-enrollment instructions can be found in the <u>Arizona VFC Re-enrollment instructions</u> or on the <u>ASIIS home page</u>.
- A reminder email was sent on 05/27/2025 via RedCap


AZ

8




Sector State St













2024-2025 School and Child Care Immunization Coverage TAPI Community Awareness Meeting June 2025 Lauren Krebs, MPH | School Health Epidemiologist



Coverage Rates - Child Care, 2021-2024			91.7% Haemophilue In	90.6%	90.3%	80.9% 91.8%	
Childcare				93.3%	82.4%		92.2%
	2023	2024	% Change 23-24	Hepstitle A	84,7%	84.5%	83,7%
Students Enrolled	71,919	67,392	-6.29%	Hepatitle B			
4+ DTaP	90.3%	89.9%	-0.4%	92.7%	92.2%	02.1%	91,4%
3+ Polio	91.9%	91.5%	-0.4%	Measles, Mump	a Rubalia		
1+ MMR	92.8%	92.4%	-0.4%	93.7%	93.0%	92,8%	92.4%
3+ HIB	92.2%	91.6%	-0.6%		22.0 1	52.03	92.4%
2+ Hep A**	84.5%	83.7%	-0.8%	Pollo			
3+ Hep B	92.1%	91.4%	-0.7%	92.1% Varicella	92.2%	91,9%	91,5%
1+ Varicella	92.5%	92.0%	-0.5%	92.3%	32.9%	92.5%	92.0%
				2021	2022	2023	2024 🛋





ARIZONA


17

Coverage Rates - Sixth Grade, 2021-2024 <sub>Sixth Grade</sub>				Hepatitis B 95.8% Measles, Mump	95.7% 8, Rubella	95.4%	95.0%
				95.6%	95.4%	95.1%	94.7%
	2023	2024	% Change 23-24	Meningecoccal	ACWY	90.1%	
Students Enrolled	82,095	82,115	+0.02%	83.5%	83.9%		89.0%
Tdap	91.0%	90.5%	-0.5%	Pollo			
MenACWY	90.1%	89.0%	-0.9%	95.2%	95.1%	94.7%	94.3%
3+ Polio	94.7%	94.3%	-0.4%	Tdap			-n-n-n-
2+ MMR	95.1%	94.7%	-0.4%		85.1%	91.0%	90.5%
3+ Hep B	95.4%	95.0%	-0.4%	Usriceita			
1+ Varicella	96.2%	95.8%	-0.4%	96.5%	96.3%	96.2%	96.8%
				2021	2022	2023	2024

































Nationally there have been 263 vaccine bills in state legislatures including those like we saw in AZ and the following:


- · Medical freedom Elimination of all childcare and school requirements
- Blood donation exclusion for vaccinated patients
- · Criminal intentional exposure to pathogens aimed at live virus vaccines
- Criminal intentions for administering mRNA vaccines
- Informed consent at administration package insert, exemption education
- Medicaid fast tracked claims for vaccine adverse events
- Off label prescribing restrictions
- · Food labels for vaccine products






















38









40


#### Communications Conversation


TAPI would like to hear from our coalition members as we work to create a strategic plan and variety of messaging to work within our new vaccine world.

#### Break Out Rooms


- . What questions are you receiving in your work environment?  $_{\odot}\,$  Those you can respond to and those you are looking for more resources to address
- .
- What questions do you yourself have or have you received in social settings? What coming concerns do you have that the coalition might help prepare for? What are two way in which TAPI can best support you during this new transitional time?


tapia





Summer TIPS Karin Szymanski TAPI





# Link to: Increasing child influenza vaccination coverage: A modeling study (Williams 2025)

#### Thank you for your interest in the following publication:

Williams K, Krauland M, Nowalk M, et al. Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling study. *Journal of Infection*. 2025;90(3):106443.

#### Please find below a link to this publication on the publisher's website:

https://doi.org/10.1016/j.jinf.2025.106443

## **Additional Information**

This information is being provided, as a professional courtesy, in response to your request. This information should in no way be construed as a recommendation for the use of any AstraZeneca products in any manner other than as approved by your country's regulatory agency and as described in the labeling information.


Your ability to access the full text on the above website may be dependent on whether you or your institution subscribes to this content.

If you are seeking additional information, you may submit your request at <u>https://contactazmedical.astrazeneca.com/</u> or go to <u>https://medicalinformation.astrazeneca.com/</u>.

Document ID: a52e5f97-2eb9-42de-bae3-248c8d813f6c Last updated: 24-February-2025

# Patient Journey for FLUMIST<sup>®</sup> (Influenza Vaccine Live, Intranasal) Ordering, Shipping & At-Home Administration





#### INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

#### IMPORTANT SAFETY INFORMATION

- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction

Please see additional Important Safety Information on next page and full Prescribing Information, including Patient Information and Instructions for Use.

# Patient Journey for FLUMIST<sup>®</sup> (Influenza Vaccine Live, Intranasal) Ordering, Shipping & At-Home Administration





#### **IMPORTANT SAFETY INFORMATION (continued)**

- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
- · The effectiveness of FLUMIST has not been studied in immunocompromised persons
- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
- · FLUMIST may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

#### INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

#### You may report side effects related to AstraZeneca products C.

Please see full Prescribing Information, including Patient Information and Instructions for Use.

<sup>a</sup>If contact information provided.

ACIP = Advisory Committee on Immunization Practices; ASPN = Asembia Specialty Pharmacy Network; CDC = Centers for Disease Control and Prevention; HCP = healthcare professional.

1. FluMist website. Coming as soon as next year: the only at-home flu vaccine, delivered with FluMist Home. Updated November 2024. Accessed February 26, 2025. <a href="https://www.flumist.com/">https://www.flumist.com/</a>; 2. In House Data, AstraZeneca. DoF REF-263898; 3. Immunize.org. Screening checklist for contraindications to live attenuated intranasal influenza vaccination. August 13, 2024. Accessed February 26, 2025. <a href="https://www.immunize.org/wp-content/uploads/catg.d/p4067.pdf">https://www.flumist.com/</a>; 4. Centers for Disease Control and Prevention. Immunize.org/wp-content/uploads/catg.d/p4067.pdf</a>; 4. Centers for Disease Control and Prevention. Immunization Information Systems Resources. May 17, 2024. Accessed February 26, 2025. <a href="https://www.cdc.gov/fils/about/index.html#cdc\_data\_surveillance">https://www.cdc.gov/fils/about/index.html#cdc\_data\_surveillance</a>; 5. Centers for Disease Control and Prevention. Influenza vaccine administration and coverage by jurisdiction, children and adults, United States. February 19, 2025. <a href="https://www.cdc.gov/fluvaxview/dashboard/vaccine-administration-coverage-jurisdiction-lis.html">https://www.cdc.gov/fluvaxview/dashboard/vaccine-administration-coverage-jurisdiction-lis.html</a>.



This product information is intended for US Health Care Professionals only. FLUMIST is a registered trademark of the AstraZeneca group of companies. ©2025 AstraZeneca. All rights reserved. US-100969 Last Updated 5/25